Rivaraoxaban dosing is based on more than just pharmacokinetic properties
Sign Up to like & getrecommendations! Published in 2017 at "British Medical Journal"
DOI: 10.1136/bmj.j608
Abstract: We at Bayer think that Moore’s letter on rivaroxaban is misleading.1 Pharmacokinetic properties are not the sole determinants of the appropriate dosing regimen, and the pharmacodynamic effect of rivaroxaban once daily is evident for the… read more here.
Keywords: pharmacokinetic properties; based pharmacokinetic; dosing based; rivaraoxaban dosing ... See more keywords